other material
confidence high
sentiment positive
materiality 0.80
ARC-9 interim analysis: EZFB combo improves PFS (HR 0.27) and OS (HR 0.37) vs regorafenib in 3L mCRC
Arcus Biosciences, Inc.
- Cohort B (n=112) met primary endpoint: PFS HR 0.27 (p<0.0001), median 6.2 vs 2.1 months.
- OS key secondary: HR 0.37 (p=0.0003), median OS 19.7 vs 9.5 months favoring EZFB.
- ORR 17.3% for EZFB vs 2.7% for regorafenib; safety profile consistent with FOLFOX/bev.
- Data selected for oral presentation at 2024 ASCO Annual Meeting on June 2, 2024.